ArticleProceedings of the National Academy of Sciences of the United States of America2003
Identification of Down's syndrome critical locus gene SIM2-s as a drug therapy target for solid tumors.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 50 citations in OpenAlex.
- Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer.PloS one · 2017Trial
- Integrative genome-wide aberrant DNA methylation and transcriptome analysis identifies diagnostic markers for colorectal cancer.Archives of toxicology · 2025Article
- The role of bHLH-PAS transcription factors in endoplasmic reticulum stress.Frontiers in molecular biosciences · 2025Review
- SIM2: Its Prognostic Significance and Oncogenic Role in Endometrial Carcinoma.OncoTargets and therapy · 2024Article
- Origin and functional diversification of PAS domain, a ubiquitous intracellular sensor.Science advances · 2023Article
- Single-minded 2 is required for left-right asymmetric stomach morphogenesis.Development (Cambridge, England) · 2021Article
- Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells.Oncogene · 2021Article
- Multiple roles of single-minded 2 in esophageal squamous cell carcinoma and its clinical implications.Cancer science · 2018Article
- SIM2l attenuates resistance to hypoxia and tumor growth by transcriptional suppression of HIF1A in uterine cervical squamous cell carcinoma.Scientific reports · 2017Article
- Identification of commonly dysregulated genes in colorectal cancer by integrating analysis of RNA-Seq data and qRT-PCR validation.Cancer gene therapy · 2015Article
- bHLH-PAS proteins in cancer.Nature reviews. Cancer · 2013Review
- Potential contribution of SIM2 and ETS2 functional polymorphisms in Down syndrome associated malignancies.BMC medical genetics · 2013Article
- Sim2 prevents entry into the myogenic program by repressing MyoD transcription during limb embryonic myogenesis.Development (Cambridge, England) · 2012Article
- High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer.PloS one · 2012Article
- Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy.The American journal of pathology · 2011Article
- Identification of residues in the N-terminal PAS domains important for dimerization of Arnt and AhR.Nucleic acids research · 2011Article
- Article
- Article
- Identification of candidate prostate cancer genes through comparative expression-profiling of seminal vesicle.The Prostate · 2008Article
- The bHLH/Per-Arnt-Sim transcription factor SIM2 regulates muscle transcript myomesin2 via a novel, non-canonical E-box sequence.Nucleic acids research · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report here a cancer drug therapy use of a gene involved in Down's syndrome. Using bioinformatics approaches, we recently predicted Single Minded 2 gene (SIM2) from Down's syndrome critical region to be specific to certain solid tumors. Involvement of SIM2 in solid tumors has not previously been reported. Intrigued by a possible association between a Down's syndrome gene and solid tumors, we monitored SIM2 expression in solid tumors. Isoform-specific expression of SIM2 short-form (SIM2-s) was seen selectively in colon, prostate, and pancreatic carcinomas but not in breast, lung, or ovarian carcinomas nor in most normal tissues. In colon tumors, SIM2-s expression was seen in early stages. Antisense inhibition of SIM2-s expression in a colon cancer cell line caused inhibition of gene expression, growth inhibition, and apoptosis. The administration of the antisense, but not the control, oligonucleotides caused a pronounced inhibition of tumor growth in nude mice with no major toxicity. Our findings provide a strong rationale for the genes-to-drugs paradigm, establish SIM2-s as a molecular target for cancer therapeutics, and may further understanding of the cancer risk of Down's syndrome patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.